CIBC started coverage on shares of Gilead Sciences, Inc. (NASDAQ:GILD) in a report published on Thursday morning. The firm issued a market perform rating on the biopharmaceutical company’s stock.

GILD has been the subject of a number of other reports. William Blair restated an outperform rating on shares of Gilead Sciences in a research note on Friday, June 16th. Morgan Stanley restated an equal weight rating on shares of Gilead Sciences in a research note on Tuesday, July 11th. Royal Bank Of Canada initiated coverage on Gilead Sciences in a research note on Thursday, September 14th. They issued an outperform rating and a $94.00 target price for the company. Robert W. Baird restated an outperform rating and issued a $87.00 target price on shares of Gilead Sciences in a research note on Tuesday, August 29th. Finally, Berenberg Bank set a $86.00 target price on Gilead Sciences and gave the company a buy rating in a research note on Tuesday, August 29th. Twelve investment analysts have rated the stock with a hold rating and twenty-one have given a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and a consensus price target of $85.66.

Gilead Sciences (NASDAQ GILD) traded down 1.64% during trading on Thursday, hitting $82.14. 5,797,031 shares of the stock traded hands. Gilead Sciences has a one year low of $63.76 and a one year high of $86.27. The company has a 50-day moving average price of $80.97 and a 200 day moving average price of $71.66. The stock has a market cap of $107.27 billion, a PE ratio of 8.92 and a beta of 1.14.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.11 by $0.45. The company had revenue of $7.14 billion during the quarter, compared to analysts’ expectations of $6.35 billion. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. The business’s revenue was down 8.2% on a year-over-year basis. During the same period last year, the business earned $3.08 earnings per share. Analysts expect that Gilead Sciences will post $8.75 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “CIBC Begins Coverage on Gilead Sciences, Inc. (GILD)” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2017/10/08/cibc-begins-coverage-on-gilead-sciences-inc-gild.html.

The business also recently disclosed a quarterly dividend, which was paid on Thursday, September 28th. Stockholders of record on Friday, September 15th were paid a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.53%. The ex-dividend date was Thursday, September 14th. Gilead Sciences’s dividend payout ratio is currently 22.58%.

In related news, CFO Robin L. Washington sold 51,820 shares of the business’s stock in a transaction that occurred on Thursday, September 7th. The stock was sold at an average price of $85.00, for a total transaction of $4,404,700.00. Following the transaction, the chief financial officer now directly owns 43,352 shares of the company’s stock, valued at approximately $3,684,920. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider John C. Martin sold 73,333 shares of the business’s stock in a transaction that occurred on Tuesday, August 1st. The stock was sold at an average price of $75.86, for a total value of $5,563,041.38. Following the transaction, the insider now directly owns 3,199,969 shares in the company, valued at $242,749,648.34. The disclosure for this sale can be found here. Insiders have sold a total of 486,819 shares of company stock worth $39,298,919 over the last three months. 1.30% of the stock is owned by insiders.

Several hedge funds have recently bought and sold shares of GILD. Waldron LP increased its holdings in shares of Gilead Sciences by 20.4% during the 1st quarter. Waldron LP now owns 10,360 shares of the biopharmaceutical company’s stock worth $711,000 after acquiring an additional 1,752 shares during the last quarter. Mycio Wealth Partners LLC grew its holdings in Gilead Sciences by 13.0% in the 1st quarter. Mycio Wealth Partners LLC now owns 10,146 shares of the biopharmaceutical company’s stock valued at $689,000 after buying an additional 1,165 shares in the last quarter. Cubic Asset Management LLC grew its holdings in Gilead Sciences by 1.9% in the 1st quarter. Cubic Asset Management LLC now owns 29,701 shares of the biopharmaceutical company’s stock valued at $2,017,000 after buying an additional 560 shares in the last quarter. Dubuque Bank & Trust Co. grew its holdings in Gilead Sciences by 19.4% in the 1st quarter. Dubuque Bank & Trust Co. now owns 1,642 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 267 shares in the last quarter. Finally, Adviser Investments LLC acquired a new position in Gilead Sciences in the 1st quarter valued at $4,218,000. 73.99% of the stock is currently owned by institutional investors and hedge funds.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.